Safety and Effectiveness of a Multifocal Intraocular Lens (IOL)

Not Applicable

Completed

Brief Summary: To evaluate the safety and effectiveness of the ZM900 Tecnis Multifocal lens. Results from two studies (an original study with 125 multifocal and 123 monofocal subjects, protocol DIOL-101-TCNS, and an expansion study with 222 additional multifocal subjects, protocol DIOL-104-TCNS) are combined to evaluate the ZM900 Tecnis Multifocal lens vs. a monofocal control. The original study was conducted in 2004-2006; the expansion study was conducted in 2007-2008. Results from both studies were analyzed together for FDA approval.

Detailed Description: The original study was protocol DIOL-101-TCNS; the expansion study was protocol DIOL-104-TCNS. The study protocols were almost identical with the exception that no control subjects were enrolled in the expansion study; only additional multifocal subjects. All eligibility criteria and testing conducted in the expansion study was the same as that in the original study. The hypotheses were that best corrected distance visual acuity of the ZM900 lens would meet or exceed the FDA grid values, complication and adverse event rates of the ZM900 would be similar to the FDA grid rates for posterior chamber IOLs, and near visual acuity of the ZM900 lens would be improved compared to that of the monofocal control lens.

Recruitment & Eligibility

Inclusion Criteria

Visual potential of 20/30 or better in each study eye
Preoperative BCDVA worse than Snellen 20/40 or worse than 20/30 in the presence of glare (as measured using a Snellen chart with BAT at medium)
Naturally dilated pupil size (in dim light) > 4.0 mm (with no dilation medications) for each study eye
Preoperative corneal astigmatism of 1.0 D or less

Exclusion Criteria

Use of systemic or ocular medications that may affect vision (the use of any miotic agent is specifically contraindicated)
Acute or chronic disease or illness that would increase the operative risk or confound the study outcome(s),(e.g., diabetes mellitus, immunocompromised, connective tissue disease, etc.)
Uncontrolled systemic or ocular disease
History of ocular trauma or prior ocular surgery or subjects expected to require retinal laser treatment or other surgical intervention
Presence of ocular pathology other than cataract such as:
- Amblyopia or strabismus
- Corneal abnormalities
- Pupil abnormalities
- Capsule or zonule abnormalities
- Intraocular inflammation
- Known pathology that may affect visual acuity and/or are predicted to cause future acuity losses to a level of 20/30 or worse (e.g. macular degeneration)
Requiring an intraocular lens outside the study diopter range
Contact lens usage prior to study procedure (time interval dependent upon contact lens type)

Primary Outcome Measures

Name	Time	Method
Number of Participants That Achieved Best Corrected Distance Visual Acuity of 20/40 or Better in the First Eye.	One year	Number of participants that achieved a best corrected distance visual acuity of 20/40 or better in the first eye. As most subjects were implanted bilaterally,"first eye" refers to the first implanted eye of each subject.
Mean Binocular Distance Corrected Near Visual Acuity in Snellen	One year	Mean binocular near visual acuity with distance correction in place measured at 33 cm; Mean is reported in Snellen (e.g. 20/20, 20/40, etc.), standard deviation reported in ETDRS (Early treatment diabetic retinopathy study)eye chart log units.

Secondary Outcome Measures